The Oncology Institute, Inc. (STLN) Reports Q2 Loss, Tops Revenue Estimates
STARLING ONCOLO (STLN) delivered earnings and revenue surprises of -14.29% and +5.55%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?